Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
greater 26 33 26 33 O
than 34 38 34 38 O
or 39 41 39 41 O
equal 42 47 42 47 O
to 48 50 48 50 O
1.5x10 51 57 51 57 B-lower_bound
^ 57 58 57 58 I-lower_bound
9 58 59 58 59 I-lower_bound
/ 59 60 59 60 I-lower_bound
L 60 61 60 61 I-lower_bound

At 0 2 62 64 O
least 3 8 65 70 O
one 9 12 71 74 B-lower_bound
prior 13 18 75 80 B-treatment
chemotherapy 19 31 81 93 I-treatment

Because 0 7 94 101 O
no 8 10 102 104 O
dosing 11 17 105 111 O
adverse 18 25 112 119 O
event 26 31 120 125 O
data 32 36 126 130 O
are 37 40 131 134 O
currently 41 50 135 144 O
available 51 60 145 154 O
on 61 63 155 157 O
the 64 67 158 161 O
use 68 71 162 165 O
of 72 74 166 168 O
topotecan 75 84 169 178 B-treatment
in 85 87 179 181 I-treatment
combination 88 99 182 193 I-treatment
with 100 104 194 198 I-treatment
VX-970 105 111 199 205 I-treatment
in 112 114 206 208 O
subjects 115 123 209 217 O
less 124 128 218 222 O
than 129 133 223 227 O
18 134 136 228 230 B-upper_bound
years 137 142 231 236 I-upper_bound
of 143 145 237 239 O
age 146 149 240 243 B-age
, 149 150 243 244 O
children 151 159 245 253 O
are 160 163 254 257 O
excluded 164 172 258 266 O
from 173 177 267 271 O
this 178 182 272 276 O
study 183 188 277 282 O
, 188 189 282 283 O
but 190 193 284 287 O
will 194 198 288 292 O
be 199 201 293 295 O
eligible 202 210 296 304 O
for 211 214 305 308 O
future 215 221 309 315 O
pediatrics 222 232 316 326 O
trials 233 239 327 333 O

Creatinine 0 10 334 344 B-clinical_variable
less 11 15 345 349 O
than 16 20 350 354 O
or 21 23 355 357 O
equal 24 29 358 363 O
to 30 32 364 366 O
1.5 33 36 367 370 B-upper_bound
mg 37 39 371 373 I-upper_bound
/ 39 40 373 374 I-upper_bound
dL 40 42 374 376 I-upper_bound
or 43 45 377 379 O
creatinine 46 56 380 390 B-clinical_variable
clearance 57 66 391 400 I-clinical_variable
by 67 69 401 403 O
Cockcroft 70 79 404 413 O
- 79 80 413 414 O
Gault 80 85 414 419 O
formula 86 93 420 427 O
greater 94 101 428 435 O
than 102 106 436 440 O
or 107 109 441 443 O
equal 110 115 444 449 O
to 116 118 450 452 O
60 119 121 453 455 B-lower_bound
mL 122 124 456 458 I-lower_bound
/ 124 125 458 459 I-lower_bound
min 125 128 459 462 I-lower_bound

ECOG 0 4 463 467 B-clinical_variable
performance 5 16 468 479 I-clinical_variable
status 17 23 480 486 I-clinical_variable
less 24 28 487 491 O
than 29 33 492 496 O
or 34 36 497 499 O
equal 37 42 500 505 O
to 43 45 506 508 O
2 46 47 509 510 B-upper_bound
( 48 49 511 512 O
Performance 49 60 512 523 O
Status 61 67 524 530 O
Criteria 68 76 531 539 O
) 76 77 539 540 O

HIV 0 3 541 544 B-chronic_disease
- 3 4 544 545 O
positive 4 12 545 553 O
subjects 13 21 554 562 O
on 22 24 563 565 O
combination 25 36 566 577 O
antiretroviral 37 51 578 592 B-treatment
therapy 52 59 593 600 I-treatment
are 60 63 601 604 O
ineligible 64 74 605 615 O
because 75 82 616 623 O
of 83 85 624 626 O
the 86 89 627 630 O
potential 90 99 631 640 O
for 100 103 641 644 O
pharmacokinetic 104 119 645 660 B-treatment
interactions 120 132 661 673 I-treatment
with 133 137 674 678 I-treatment
VX-970 138 144 679 685 I-treatment
. 144 145 685 686 O
In 146 148 687 689 O
addition 149 157 690 698 O
, 157 158 698 699 O
these 159 164 700 705 O
subjects 165 173 706 714 O
are 174 177 715 718 O
at 178 180 719 721 O
increased 181 190 722 731 O
risk 191 195 732 736 O
of 196 198 737 739 O
lethal 199 205 740 746 B-chronic_disease
infections 206 216 747 757 I-chronic_disease
when 217 221 758 762 O
treated 222 229 763 770 O
with 230 234 771 775 O
marrow 235 241 776 782 B-treatment
- 241 242 782 783 I-treatment
suppressive 242 253 783 794 I-treatment
therapy 254 261 795 802 I-treatment

Hemoglobin 0 10 803 813 B-clinical_variable
greater 11 18 814 821 O
than 19 23 822 826 O
or 24 26 827 829 O
equal 27 32 830 835 O
to 33 35 836 838 O
9.0 36 39 839 842 B-lower_bound
g 40 41 843 844 I-lower_bound
/ 41 42 844 845 I-lower_bound
dL 42 44 845 847 I-lower_bound

Histological 0 12 848 860 O
confirmation 13 25 861 873 O
of 26 28 874 876 O
SCLC 29 33 877 881 B-cancer
, 33 34 881 882 O
or 35 37 883 885 O
extrapulmonary 38 52 886 900 B-cancer
small 53 58 901 906 I-cancer
cell 59 63 907 911 I-cancer
cancer 64 70 912 918 I-cancer
. 70 71 918 919 O
Although 72 80 920 928 O
NCI 81 84 929 932 O
confirmation 85 97 933 945 O
of 98 100 946 948 O
pathology 101 110 949 958 O
is 111 113 959 961 O
not 114 117 962 965 O
required 118 126 966 974 O
prior 127 132 975 980 O
to 133 135 981 983 O
starting 136 144 984 992 O
treatment 145 154 993 1002 B-treatment
, 154 155 1002 1003 O
every 156 161 1004 1009 O
effort 162 168 1010 1016 O
will 169 173 1017 1021 O
be 174 176 1022 1024 O
made 177 181 1025 1029 O
to 182 184 1030 1032 O
obtain 185 191 1033 1039 O
outside 192 199 1040 1047 O
pathology 200 209 1048 1057 O
to 210 212 1058 1060 O
be 213 215 1061 1063 O
reviewed 216 224 1064 1072 O
by 225 227 1073 1075 O
an 228 230 1076 1078 O
NCI 231 234 1079 1082 O
pathologist 235 246 1083 1094 O

History 0 7 1095 1102 O
of 8 10 1103 1105 O
allergic 11 19 1106 1114 O
reactions 20 29 1115 1124 O
attributed 30 40 1125 1135 O
to 41 43 1136 1138 O
compounds 44 53 1139 1148 O
of 54 56 1149 1151 O
similar 57 64 1152 1159 O
chemical 65 73 1160 1168 O
or 74 76 1169 1171 O
biologic 77 85 1172 1180 O
composition 86 97 1181 1192 O
to 98 100 1193 1195 O
( 101 102 1196 1197 O
study 102 107 1197 1202 B-treatment
agent 108 113 1203 1208 I-treatment
) 113 114 1208 1209 O
or 115 117 1210 1212 O
other 118 123 1213 1218 O
agents 124 130 1219 1225 O
used 131 135 1226 1230 O
in 136 138 1231 1233 O
study 139 144 1234 1239 O

Male 0 4 1240 1244 B-gender

NSCLC 0 5 1245 1250 B-cancer
subjects 6 14 1251 1259 O
with 15 19 1260 1264 O
EGFR 20 24 1265 1269 O
mutations 25 34 1270 1279 O
or 35 37 1280 1282 O
ALK 38 41 1283 1286 O
translocations 42 56 1287 1301 O
should 57 63 1302 1308 O
have 64 68 1309 1313 O
previously 69 79 1314 1324 O
received 80 88 1325 1333 O
appropriate 89 100 1334 1345 O
FDA 101 104 1346 1349 B-treatment
approved 105 113 1350 1358 I-treatment
therapies 114 123 1359 1368 I-treatment
in 124 126 1369 1371 O
addition 127 135 1372 1380 O
to 136 138 1381 1383 O
prior 139 144 1384 1389 B-treatment
chemotherapy 145 157 1390 1402 I-treatment

Patients 0 8 1403 1411 O
must 9 13 1412 1416 O
have 14 18 1417 1421 O
measurable 19 29 1422 1432 B-chronic_disease
disease 30 37 1433 1440 I-chronic_disease
, 37 38 1440 1441 O
per 39 42 1442 1445 O
RECIST 43 49 1446 1452 O
1.1 50 53 1453 1456 O
. 53 54 1456 1457 O
Subjects 55 63 1458 1466 O
with 64 68 1467 1471 O
evaluable 69 78 1472 1481 O
, 78 79 1481 1482 O
but 80 83 1483 1486 O
not 84 87 1487 1490 O
measurable 88 98 1491 1501 O
disease 99 106 1502 1509 O
will 107 111 1510 1514 O
be 112 114 1515 1517 O
eligible 115 123 1518 1526 O
for 124 127 1527 1530 O
Phase 128 133 1531 1536 O
1 134 135 1537 1538 O

Platelets 0 9 1539 1548 B-clinical_variable
greater 10 17 1549 1556 O
than 18 22 1557 1561 O
or 23 25 1562 1564 O
equal 26 31 1565 1570 O
to 32 34 1571 1573 O
100x10 35 41 1574 1580 B-lower_bound
^ 41 42 1580 1581 I-lower_bound
9 42 43 1581 1582 I-lower_bound
/ 43 44 1582 1583 I-lower_bound
L 44 45 1583 1584 I-lower_bound

Subjects 0 8 1585 1593 O
must 9 13 1594 1598 O
not 14 17 1599 1602 O
have 18 22 1603 1607 O
received 23 31 1608 1616 O
chemotherapy 32 44 1617 1629 B-treatment
, 44 45 1629 1630 O
or 46 48 1631 1633 O
undergone 49 58 1634 1643 O
major 59 64 1644 1649 B-treatment
surgery 65 72 1650 1657 I-treatment
within 73 79 1658 1664 O
4 80 81 1665 1666 B-upper_bound
weeks 82 87 1667 1672 I-upper_bound
and 88 91 1673 1676 O
radiotherapy 92 104 1677 1689 B-treatment
within 105 111 1690 1696 O
24 112 114 1697 1699 B-upper_bound
hours 115 120 1700 1705 I-upper_bound
prior 121 126 1706 1711 I-upper_bound
to 127 129 1712 1714 O
enrollment 130 140 1715 1725 O

Subjects 0 8 1726 1734 O
requiring 9 18 1735 1744 O
any 19 22 1745 1748 O
medications 23 34 1749 1760 B-treatment
or 35 37 1761 1763 O
substances 38 48 1764 1774 O
that 49 53 1775 1779 O
are 54 57 1780 1783 O
strong 58 64 1784 1790 B-treatment
inhibitors 65 75 1791 1801 I-treatment
or 76 78 1802 1804 I-treatment
inducers 79 87 1805 1813 I-treatment
of 88 90 1814 1816 I-treatment
CYP3A 91 96 1817 1822 I-treatment
during 97 103 1823 1829 O
the 104 107 1830 1833 O
course 108 114 1834 1840 O
of 115 117 1841 1843 O
the 118 121 1844 1847 O
study 122 127 1848 1853 O
are 128 131 1854 1857 O
ineligible 132 142 1858 1868 O
. 142 143 1868 1869 O
Lists 144 149 1870 1875 O
including 150 159 1876 1885 O
strong 160 166 1886 1892 B-treatment
inhibitors 167 177 1893 1903 I-treatment
and 178 181 1904 1907 I-treatment
inducers 182 190 1908 1916 I-treatment
of 191 193 1917 1919 I-treatment
CYP 194 197 1920 1923 I-treatment
3A4 198 201 1924 1927 I-treatment
are 202 205 1928 1931 O
provided 206 214 1932 1940 O

Subjects 0 8 1941 1949 O
who 9 12 1950 1953 O
are 13 16 1954 1957 O
receiving 17 26 1958 1967 O
any 27 30 1968 1971 O
other 31 36 1972 1977 O
investigational 37 52 1978 1993 B-treatment
agents 53 59 1994 2000 I-treatment

Subjects 0 8 2001 2009 O
with 9 13 2010 2014 O
both 14 18 2015 2019 O
platinum 19 27 2020 2028 O
- 27 28 2028 2029 O
sensitive 28 37 2029 2038 O
and 38 41 2039 2042 O
platinum 42 50 2043 2051 B-chronic_disease
- 50 51 2051 2052 I-chronic_disease
refractory 51 61 2052 2062 I-chronic_disease
disease 62 69 2063 2070 I-chronic_disease

Subjects 0 8 2071 2079 O
with 9 13 2080 2084 O
evidence 14 22 2085 2093 O
of 23 25 2094 2096 O
severe 26 32 2097 2103 O
or 33 35 2104 2106 O
uncontrolled 36 48 2107 2119 B-chronic_disease
systemic 49 57 2120 2128 I-chronic_disease
disease 58 65 2129 2136 I-chronic_disease
, 65 66 2136 2137 O
or 67 69 2138 2140 O
any 70 73 2141 2144 O
concurrent 74 84 2145 2155 O
condition 85 94 2156 2165 O
, 94 95 2165 2166 O
which 96 101 2167 2172 O
could 102 107 2173 2178 O
compromise 108 118 2179 2189 O
participation 119 132 2190 2203 O
in 133 135 2204 2206 O
the 136 139 2207 2210 O
study 140 145 2211 2216 O
, 145 146 2216 2217 O
including 147 156 2218 2227 O
, 156 157 2227 2228 O
but 158 161 2229 2232 O
not 162 165 2233 2236 O
limited 166 173 2237 2244 O
to 174 176 2245 2247 O
, 176 177 2247 2248 O
active 178 184 2249 2255 O
or 185 187 2256 2258 O
uncontrolled 188 200 2259 2271 O
infection 201 210 2272 2281 O
, 210 211 2281 2282 O
immune 212 218 2283 2289 B-chronic_disease
deficiencies 219 231 2290 2302 I-chronic_disease
, 231 232 2302 2303 O
Hepatitis 233 242 2304 2313 B-chronic_disease
B 243 244 2314 2315 I-chronic_disease
, 244 245 2315 2316 O
Hepatitis 246 255 2317 2326 B-chronic_disease
C 256 257 2327 2328 I-chronic_disease
, 257 258 2328 2329 O
uncontrolled 259 271 2330 2342 B-chronic_disease
diabetes 272 280 2343 2351 I-chronic_disease
, 280 281 2351 2352 O
uncontrolled 282 294 2353 2365 B-chronic_disease
hypertension 295 307 2366 2378 I-chronic_disease
, 307 308 2378 2379 O
symptomatic 309 320 2380 2391 B-chronic_disease
congestive 321 331 2392 2402 I-chronic_disease
heart 332 337 2403 2408 I-chronic_disease
failure 338 345 2409 2416 I-chronic_disease
, 345 346 2416 2417 O
unstable 347 355 2418 2426 B-chronic_disease
angina 356 362 2427 2433 I-chronic_disease
pectoris 363 371 2434 2442 I-chronic_disease
, 371 372 2442 2443 O
myocardial 373 383 2444 2454 B-chronic_disease
infarction 384 394 2455 2465 I-chronic_disease
within 395 401 2466 2472 O
the 402 405 2473 2476 O
past 406 410 2477 2481 B-upper_bound
6 411 412 2482 2483 I-upper_bound
months 413 419 2484 2490 I-upper_bound
, 419 420 2490 2491 O
uncontrolled 421 433 2492 2504 B-chronic_disease
cardiac 434 441 2505 2512 I-chronic_disease
arrhythmia 442 452 2513 2523 I-chronic_disease
, 452 453 2523 2524 O
stroke 454 460 2525 2531 B-chronic_disease
/ 460 461 2531 2532 I-chronic_disease
cerebrovascular 461 476 2532 2547 I-chronic_disease
accident 477 485 2548 2556 I-chronic_disease
within 486 492 2557 2563 O
the 493 496 2564 2567 O
past 497 501 2568 2572 O
6 502 503 2573 2574 O
months 504 510 2575 2581 O
, 510 511 2581 2582 O
or 512 514 2583 2585 O
psychiatric 515 526 2586 2597 B-chronic_disease
illness 527 534 2598 2605 I-chronic_disease
/ 534 535 2605 2606 I-chronic_disease
social 535 541 2606 2612 I-chronic_disease
situations 542 552 2613 2623 I-chronic_disease
which 553 558 2624 2629 O
would 559 564 2630 2635 O
jeopardize 565 575 2636 2646 O
compliance 576 586 2647 2657 O
with 587 591 2658 2662 O
the 592 595 2663 2666 O
protocol 596 604 2667 2675 O

Subjects 0 8 2676 2684 O
with 9 13 2685 2689 O
histologically 14 28 2690 2704 O
confirmed 29 38 2705 2714 O
SCLC 39 43 2715 2719 B-cancer
, 43 44 2719 2720 O
NSCLC 45 50 2721 2726 B-cancer
, 50 51 2726 2727 O
ovarian 52 59 2728 2735 B-cancer
cancer 60 66 2736 2742 I-cancer
, 66 67 2742 2743 O
cervical 68 76 2744 2752 B-cancer
cancer 77 83 2753 2759 I-cancer
, 83 84 2759 2760 O
and 85 88 2761 2764 O
neuroendocrine 89 103 2765 2779 B-cancer
cancers 104 111 2780 2787 I-cancer

Subjects 0 8 2788 2796 O
with 9 13 2797 2801 O
symptomatic 14 25 2802 2813 O
brain 26 31 2814 2819 B-cancer
metastases 32 42 2820 2830 I-cancer
will 43 47 2831 2835 O
be 48 50 2836 2838 O
excluded 51 59 2839 2847 O
from 60 64 2848 2852 O
trial 65 70 2853 2858 O
secondary 71 80 2859 2868 O
to 81 83 2869 2871 O
poor 84 88 2872 2876 O
prognosis 89 98 2877 2886 O

Subjects 0 8 2887 2895 O
with 9 13 2896 2900 O
tumor 14 19 2901 2906 B-cancer
amenable 20 28 2907 2915 O
to 29 31 2916 2918 O
potentially 32 43 2919 2930 O
curative 44 52 2931 2939 B-treatment
therapy 53 60 2940 2947 I-treatment

Total 0 5 2948 2953 B-clinical_variable
Bilirubin 6 15 2954 2963 I-clinical_variable
less 16 20 2964 2968 O
than 21 25 2969 2973 O
or 26 28 2974 2976 O
equal 29 34 2977 2982 O
to 35 37 2983 2985 O
2.0 38 41 2986 2989 B-upper_bound
mg 42 44 2990 2992 I-upper_bound
/ 44 45 2992 2993 I-upper_bound
dL 45 47 2993 2995 I-upper_bound

Transaminases 0 13 2996 3009 B-clinical_variable
less 14 18 3010 3014 O
than 19 23 3015 3019 O
or 24 26 3020 3022 O
equal 27 32 3023 3028 O
to 33 35 3029 3031 O
2 36 37 3032 3033 B-upper_bound
x 38 39 3034 3035 I-upper_bound
ULN 40 43 3036 3039 I-upper_bound
or 44 46 3040 3042 O
if 47 49 3043 3045 O
liver 50 55 3046 3051 B-cancer
metastases 56 66 3052 3062 I-cancer
were 67 71 3063 3067 O
present 72 79 3068 3075 O
, 79 80 3075 3076 O
less 81 85 3077 3081 O
than 86 90 3082 3086 O
or 91 93 3087 3089 O
equal 94 99 3090 3095 O
to 100 102 3096 3098 O
3xULN 103 108 3099 3104 B-upper_bound

female 0 6 3105 3111 B-gender
subjects 7 15 3112 3120 I-gender

greater 0 7 3121 3128 O
than 8 12 3129 3133 O
or 13 15 3134 3136 O
equal 16 21 3137 3142 O
to 22 24 3143 3145 O
18 25 27 3146 3148 B-lower_bound
years 28 33 3149 3154 I-lower_bound
of 34 36 3155 3157 O
age 37 40 3158 3161 B-age

subjects 0 8 3162 3170 O
who 9 12 3171 3174 O
have 13 17 3175 3179 O
had 18 21 3180 3183 O
treatment 22 31 3184 3193 B-treatment
for 32 35 3194 3197 O
their 36 41 3198 3203 O
brain 42 47 3204 3209 B-cancer
metastasis 48 58 3210 3220 I-cancer
and 59 62 3221 3224 O
whose 63 68 3225 3230 O
brain 69 74 3231 3236 B-chronic_disease
disease 75 82 3237 3244 I-chronic_disease
is 83 85 3245 3247 O
stable 86 92 3248 3254 O
without 93 100 3255 3262 O
steroid 101 108 3263 3270 B-treatment
therapy 109 116 3271 3278 I-treatment
for 117 120 3279 3282 O
1 121 122 3283 3284 B-upper_bound
week 123 127 3285 3289 I-upper_bound
or 128 130 3290 3292 O
on 131 133 3293 3295 O
physiologic 134 145 3296 3307 O
doses 146 151 3308 3313 O
of 152 154 3314 3316 O
steroids 155 163 3317 3325 B-treatment
may 164 167 3326 3329 O
be 168 170 3330 3332 O
enrolled 171 179 3333 3341 O

